Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin

British Journal of Cancer

Volumn 80, Issue 8, 1999, Pages 1245-1251

  Kovacs, M S ^a   Hocking, D J ^a   Evans, J W ^a   Siim, B G ^a,b   Wouters, B G ^a   Brown, J M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cisplatin; DNA interstrand cross links; Hypoxia; Nucleotide excision repair; Tirapazamine

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; OXYGEN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TIRAPAZAMINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL HYPOXIA; CELL MUTANT; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIZATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CHO CELLS; CISPLATIN; CRICETINAE; CROSS-LINKING REAGENTS; DNA DAMAGE; DNA REPAIR; DRUG INTERACTIONS; HUMANS; LUNG NEOPLASMS; MICE; TRIAZINES;

EID: 0033063810     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690492     Document Type: Article

References (40)

1. Adam M, Gabalski EC, Ochlert JW, Bloch DA, Brown JM, Elsaid AA, Pinto HA and Terris DJ (1999) Tissue oxygen distribution in head and neck patients. Head Neck 21: 146-153
2. Andersson BS, Sadeghi T, Siciliano MJ, Legerski R and Murray D (1996) Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother Pharmacol 38: 406-416
3. Berezney R and Coffey DS (1975) Nuclear protein matrix: association with newly synthesized DNA. Science 189: 291-293
4. Brizel DM, Rosner GL, Harrelson J, Prosnitz LR and Dewhirst MW (1994) Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 30: 635-642
5. Brizel DM, Sibley GS, Prosnitz LR, Scher RL and Dewhirst MW (1997) Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38: 285-289
6. Brown JM (1993) SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67: 1163-1170
7. Brown JM and Lemmon MJ (1990) Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50: 7745-7749
8. Brown JM and Lemmon MJ (1991) Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys 20: 457-461
9. Cook PR (1989) The nucleoskeleton and the topology of transcription. Eur J Biochem 185: 487-501
10. 2 distribution in human malignant brain tumours. Adv Exp Med Biol 345: 465-470
11. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C and Reed E (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84: 1512-1517
12. Damia G, Imperatori L, Stefanini M and D'Incalci M (1996) Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti cancer agents. Int J Cancer 66: 779-783
13. Delahoussaye YM, Wouters BG, Evans JE and Brown JM (1997) Intranuclear metabolism of tirapazamine by matrix-associated reductases. Proc Am Assoc Cancer Res 38: 163 (abstr. # 1095)
14. Dorie MJ and Brown JM (1993) Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53: 4633-4636
15. Dorie MJ and Brown JM (1997) Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol 39: 361-366
16. Durand RE (1994) The influence of microenvironmental factors during cancer therapy. In vivo 8: 691-702
17. Evans JE, Yudoh K, Delahoussaye YM and Brown JM (1998) Tirapazamine is metabolized to its DNA damaging radical by intranuclear enzymes. Cancer Res 58: 2098-2101
18. Ewig RA and Kohn KW (1978) DNA-protein cross-linking and DNA interstrand cross-linking by haloethylnitrosoureas in L1210 cells. Cancer Res 38: 3197-3203
19. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ and Hartz WH (1988) Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14: 831-838
20. Graham MA, Senan S, Robin H, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, von Roemeling R and Workman P (1997) Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose escalation strategy in a phase I trial. Cancer Chemother Pharmacokin 40: 1-10
21. Grau C and Overgaard J (1988) Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 13: 301-309
22. Hansson J, Lewensohn R, Ringborg U and Nilsson B (1987) Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res 47: 2631-2637
23. Helmlinger G, Yuan F, Dellian M and Jain RK (1997) Interstitial pH and pO, gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3: 177-182
24. Hockel M, Schlenger K, Knoop C and Vaupel P (1991) Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O, tension measurements. Cancer Res 51: 6098-6102
25. Jones NJ, Stewart SA and Thompson LH (1990) Biochemical and genetic analysis of the Chinese hamster mutants irs1 and irs2 and their comparison to cultured ataxia telangiectasia cells. Mutagenesis 5: 15-23
26. Kim IH and Brown JM (1994) Reoxygenation and rehypoxiation in the SCCVII mouse tumor. Int J Radiat Oncol Biol Phys 29: 493-497
27. Koch CJ (1993) Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 53: 3992-3997
28. Miller VA, Ng KK, Grant SC, Kindler H, Pizzo B, Heelan RT, von Roemeling R and Kris MG (1997) Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 8: 1269-1271
29. Nordsmark M, Bentzen SM and Overgaard J (1994) Measurement of human tumour oxygenation status by a polarographic needle electrode. Acta Oncol 33: 383-389
30. Nordsmark M, Overgaard M and Overgaard J (1996) Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41: 31-40
31. Rodriguez GI, Valdivieso M, Von Hoff DD, Kraut M, Burris HA, Eckardt JR, Lockwood G, Kennedy H and von Roemeling R (1996) A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 15: 382 (abstract)
32. Siemann DW (1996) The in situ tumour response to combinations of cyclophosphamide and tirapazamine. Br J Cancer 74: S65-69
33. Siemann DW and Hinchman CA (1998) Potentiation of cisplatin activity by the bioreductive agent tirapazamine. Radiother Oncol 47: 215-220
34. Treat J, Haynes B, Johnson E, Belani C, Greenberg R, Rodriquez R, Drobbins P, Miller WJ, Meehan L and von Roemeling R (1997) Tirapazamine with cisplatin: a phase II trial in advanced stage non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16: 1633 (abstract)
35. Treat J, Johnson E, Langer C, Belani C, Haynes B, Greenberg R, Rodriquez R, Drobins P, Miller W, Jr Meehan L, McKeon A, Devin J, von Roemeling R and Viallet J (1998) Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 16: 3524-3527
36. Urtasun RC, Chapman JD, Raleigh JA, Franko AJ and Koch CJ (1986) Binding of 3H-misonidazole to solid human tumors as a measure of tumor hypoxia. Int J Radiat Oncol Biol Phys 12: 1263-1267
37. 2 histography. In Tumor Oxygenation. Vaupel PW, Kelleher DK and Gunderoth M (ed) pp. 219-232. Gustav Fischer Verlag: Stuttgart
38. 2 tension measurements. Cancer Res 51: 3316-3322
39. von Pawel J and von Roemeling R (1998) Survival benefit from tirazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: final results from the international phase III CATAPULT 1 trial. Proc Am Soc Clin Oncol 17: 454a (Abstract)
40. Zeman EM, Brown JM, Lemmon MJ, Hirst VK and Lee WW (1986) SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12: 1239-1242